Holen Sie sich die Stockscreener-App
60.10
2.11%
1.28
Crispr Therapeutics Ag Aktie (CRSP) Neueste Nachrichten
Virtu Financial LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
HC Wainwright Issues Positive Outlook for CRSP Earnings - MarketBeat
Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025 - Seeking Alpha
Benjamin Edwards Inc. Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Blair William & Co. IL Cuts Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics Bets Big On Gene-Editing Breakthroughs - Finimize
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Cetera Investment Advisers - MarketBeat
Crispr Therapeutics Faces Stock Dip Amid Promising Developments - MSN
Crispr Therapeutics shares rise 1.10% premarket after Metagenomi reported positive business updates and financial results. - AInvest
Can Rising Casgevy Sales Aid CRISPR Therapeutics Post Q2 Earnings? - Yahoo Finance
Chardan Capital Has Strong Estimate for CRSP FY2026 Earnings - MarketBeat
Westwood Holdings Group Inc. Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Research Analysts Issue Forecasts for CRSP FY2025 Earnings - MarketBeat
3 Monster Stocks in the Making to Buy Right Now - AOL.com
Barclays Forecasts Strong Price Appreciation for CRISPR Therapeutics (NASDAQ:CRSP) Stock - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Given New $80.00 Price Target at HC Wainwright - MarketBeat
CRISPR Therapeutics (CRSP) Soars 18% After $51-Million Insider Trading - MSN
Q3 EPS Estimate for CRISPR Therapeutics Boosted by Analyst - MarketBeat
CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates - MSN
Equities Analysts Issue Forecasts for CRSP FY2027 Earnings - MarketBeat
CRISPR Therapeutics AG Insider Buying: Douglas Treco Acquires 20,000 Shares - AInvest
CRISPR Therapeutics (NASDAQ:CRSP) Given "Buy" Rating at Chardan Capital - MarketBeat
Crispr Therapeutics AG (CRSP) Gets a Buy from Truist Financial - The Globe and Mail
Royal Bank Of Canada Increases CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $42.00 - MarketBeat
Director Makes Bold Move with Major Stock Purchase in Crispr Therapeutics AG! - TipRanks
IQ EQ FUND MANAGEMENT IRELAND Ltd Has $2.22 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Here is What to Know Beyond Why CRISPR Therapeutics AG (CRSP) is a Trending Stock - MSN
Crispr Therapeutics price target raised to $12 from $10 at Barclays - TipRanks
CRISPR Therapeutics (NASDAQ:CRSP) Posts Quarterly Earnings Results - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap DownHere's Why - MarketBeat
Crispr Therapeutics AG Receives Buy Rating and $56 Price Target from Leerink Partners - AInvest
CRSP Stock Analysis: What’s Going on with Crispr Therapeutics AG? - Markets.com
Crispr Therapeutics AG: Strong Sales Growth and Global Expansion Justify Buy Rating - TipRanks
Leerink Partnrs Has Pessimistic View of CRSP Q3 Earnings - MarketBeat
CRISPR Therapeutics stock price target raised to $80 by H.C. Wainwright - Investing.com Nigeria
Banque Cantonale Vaudoise Makes New Investment in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Privium Fund Management B.V. Acquires 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Earnings: Casgevy Launch Gains Momentum; Early-Stage Pipeline Progresses; Shares Undervalued - Morningstar
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption - MSN
0.07%
0.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):